glp-1 agonist structure receptor agonist-1 | CAS#:2230197-64-3 BioWorld

Learn why it happens and discover Strive's Digest, a science-backed supplement for gentle, effective relief

In clinical trials, people using GLP-1 drugs lost an average of about 10 pounds more than people using a placebo

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved a new indication for Wegovy (semaglutide) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes.

But despite widespread use of these drugs by perimenopausal women, research has largely ignored the unique risks and potential opportunities for optimizing health that GLP-1s may pose for this population.

This includes integrating the latest clinical trial data and delving into potential signaling pathways and pharmacological mechanisms

This Comment highlights emerging evidence and advocates for clinical strategies that prioritize muscle preservation to ensure the long-term success and safety of pharmacological weight management.